Could taking breaks from skin cancer drug keep it working?

NCT ID NCT04806646

Ongoing Disease control Sponsor: Gruppo Oncologico del Nord-Ovest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new way of taking the drug sonidegib for people with advanced basal cell carcinoma that cannot be surgically removed. Instead of taking the drug continuously, patients who have already achieved a complete response will take it in cycles with breaks (14 days on/14 days off or 7 days on/21 days off). The goal is to see if this tailored schedule helps patients stay cancer-free for 12 months while reducing side effects and improving quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sonidegib (Odomzo)
What this could lead to: If successful, this could offer a way for patients with advanced BCC to maintain their response with fewer drug side effects by taking breaks from treatment.
What could go wrong: This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The tailored schedule might not work for all patients, and side effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED BASAL CELL CARCINOMA

Contacts and locations

Locations

Asst Degli Spedali Civili Di Brescia

Brescia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.